By Ed Silverman
Senior Writer, Pharmalot
October 27, 2026
In an escalation of the ongoing national conflict between pharmaceutical giants and the safety-net healthcare system, Missouri Attorney General Catherine Hanaway (R) has issued a formal cease-and-desist letter to Eli Lilly. The move marks a significant tightening of the regulatory screws on drug manufacturers who have unilaterally implemented restrictive policies regarding the federal 340B Drug Pricing Program.
At the heart of the dispute is a contentious requirement: Eli Lilly has mandated that hospitals submit sensitive patient claims data as a prerequisite for receiving statutory discounts on medicines. Attorney General Hanaway’s intervention suggests that state-level authorities are increasingly willing to challenge the market power of pharmaceutical companies when those actions threaten the financial viability of local healthcare providers.
The Core Conflict: 340B and the Data Mandate
The 340B Drug Pricing Program, established by Congress in 1992, requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations—often referred to as "covered entities"—at significantly reduced prices. The intent of the program is to allow these organizations, which include community health centers, disproportionate share hospitals, and children’s hospitals, to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.
For years, the program operated with relative stability. However, as drug prices have soared, pharmaceutical companies have sought ways to limit their exposure to the program’s mandatory discounts. Eli Lilly, along with several other major manufacturers, began implementing policies requiring covered entities to upload detailed claims data—often through third-party platforms—to continue accessing 340B pricing for drugs dispensed through contract pharmacies.
Hospitals have largely resisted these requirements, citing privacy concerns, the administrative burden of data submission, and the legal argument that the 340B statute contains no such requirement for data sharing. Attorney General Hanaway’s letter asserts that by conditioning access to these discounts on the provision of such data, Eli Lilly is effectively circumventing federal law.
Chronology of the Escalating Dispute
The friction between Eli Lilly and the Missouri Attorney General’s office did not occur in a vacuum. It is the culmination of a multi-year tug-of-war between the industry and the government:
- 2020–2022: Pharmaceutical manufacturers began unilaterally restricting 340B discounts on drugs dispensed at contract pharmacies, citing concerns over "duplicate discounts" and a lack of transparency.
- Early 2024: Eli Lilly formalized its policy requiring hospitals to submit specific claims data to its designated platforms to verify the eligibility of 340B prescriptions.
- Mid-2025: Several healthcare systems in Missouri began reporting increased friction with Lilly’s verification platforms, noting that even when they complied with requests for data, the discounts were frequently denied or delayed.
- October 26, 2026: Attorney General Catherine Hanaway issues a formal cease-and-desist letter to Eli Lilly. The letter serves as a legal warning that the state views the company’s current practices as a violation of state consumer protection and fair business laws.
- The Deadline: The Attorney General has demanded that Eli Lilly formally end its data-submission requirement by November 26, 2026.
The Case of University of Missouri Health Care
The focal point of the Attorney General’s letter is the experience of University of Missouri Health Care (UMHC), a major provider operating seven hospitals across the state. Despite being a cornerstone of Missouri’s healthcare infrastructure, UMHC found itself caught in the crosshairs of the drugmaker’s policy.
According to the documentation provided by the Attorney General’s office, UMHC made a good-faith effort to comply with Eli Lilly’s demands. Recognizing the financial necessity of the 340B discounts, the hospital system agreed to provide the required claims data. However, the result was not the restoration of discounts, but continued denials.
Hanaway’s letter characterizes this as a "broken promise." By failing to provide the discounts even after the hospital system met the manufacturer’s arbitrary data requirements, the Attorney General argues that Eli Lilly has engaged in "false and misleading statements." From the perspective of the state, this is not merely a contract dispute; it is an issue of fair trade and the protection of the state’s healthcare safety net.
Supporting Data and Legal Arguments
The legal argument presented by Hanaway rests on the premise that the 340B program is a statutory mandate, not a voluntary agreement that manufacturers can alter at will. Under federal law, manufacturers participating in Medicaid are required to sign a Pharmaceutical Pricing Agreement (PPA) with the Secretary of Health and Human Services.
Key Points of Contention:
- Statutory Compliance: The Attorney General argues that the 340B statute is explicit. It does not grant manufacturers the authority to create additional "gatekeeping" conditions—such as the submission of claims data—as a prerequisite for honoring the statutorily defined price.
- State Consumer Protection: By framing the issue through the lens of state law, Hanaway is bypassing the often-sluggish federal regulatory process. This tactic is becoming a popular strategy for state AGs who feel that the Health Resources and Services Administration (HRSA) has not been aggressive enough in policing manufacturer behavior.
- Financial Impact: Hospitals argue that the loss of 340B savings directly correlates to reduced access to care for low-income and uninsured patients. With pharmacy margins already thin, the administrative cost of complying with, and the financial cost of losing, these discounts creates an existential threat to some rural clinics.
Official Responses: A Tale of Two Perspectives
The Attorney General’s Office
In her correspondence, Attorney General Hanaway emphasized that the state of Missouri has a vested interest in the financial health of its hospitals. The letter warns that failure to comply with the cease-and-desist order could lead to further legal action, including potential litigation under state consumer protection statutes. "Missourians depend on these hospitals," the office noted in a press release. "When a corporation unilaterally restricts access to life-saving medicines for its own profit, the state will step in."
Eli Lilly and the Industry Stance
While Eli Lilly has not yet provided a detailed public response to the October 26 letter, the pharmaceutical industry’s general position has remained consistent. Companies argue that the 340B program, in its current, unregulated form, is prone to abuse. They contend that the expansion of contract pharmacy networks has created a "shadow market" where it is impossible to track whether a discount is being applied appropriately.
"We are committed to providing access to our medicines," a spokesperson for an industry trade group noted in a recent comment regarding similar disputes. "However, transparency is essential. Without the ability to verify claims, the 340B program lacks the integrity required to prevent duplicate discounts and ensure that savings are actually reaching the patients who need them most."
Broader Implications for the Healthcare Sector
The Missouri action is a harbinger of a more litigious future for the 340B program. As the federal government struggles to find a middle ground, state attorneys general are filling the void. This trend has several critical implications:
1. The Fragmentation of Compliance
If states begin setting different standards for how 340B pricing is handled, pharmaceutical companies will face a "patchwork" of compliance requirements. This could lead to a scenario where a manufacturer is in compliance in one state but facing a lawsuit in another, potentially forcing a national policy change to avoid the legal complexity.
2. The Shift to "Transparency vs. Privacy"
The conflict over claims data is effectively a battle over the ownership of patient information. Hospitals argue that sharing patient-level data with a third-party vendor hired by a drug company creates significant HIPAA and patient privacy risks. Manufacturers argue that without this data, they are flying blind. This debate will likely reach the federal courts soon, as the balance between patient privacy and corporate transparency becomes increasingly delicate.
3. Increased Pressure on Congress
The involvement of state-level officials is a clear signal to Congress that the current legislative ambiguity regarding 340B is unsustainable. There is growing bipartisan pressure for a legislative overhaul that would either explicitly codify the rights of manufacturers to request data or explicitly forbid it, thereby ending the reliance on "cease-and-desist" letters and executive-level squabbling.
Conclusion
The standoff between Missouri and Eli Lilly is more than just a bureaucratic dispute over pharmacy claims; it is a fundamental test of how the American healthcare system balances the profits of the pharmaceutical industry with the survival of the safety-net providers that serve the most vulnerable populations.
As the November 26 deadline approaches, all eyes will be on whether Eli Lilly chooses to challenge the Missouri Attorney General in court, or if it will seek a settlement that restores access to discounts for Missouri’s hospitals. For now, the action taken by Catherine Hanaway serves as a bold warning to the industry: the era of unilateral 340B policy changes may be nearing its limit as states reclaim their role as the primary defenders of their healthcare systems.
